16 September 2026 editorial review · Item
Low-dose interleukin-2 (IL-2): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Low-dose IL2 dose-finding expands Tregs; subgroup preservation does not establish clinical onset delay. Current engineered-IL2 and aldesleukin registries remain recruiting; no posted efficacy.
- Registry NCT07142252: RECRUITING; updated 2026-09-08; enrollment 66 (ESTIMATED); primary completion 2028-05-25 (ESTIMATED); results not posted in retrieved record.
- Registry NCT05153070: RECRUITING; updated 2026-09-09; enrollment 24 (ESTIMATED); primary completion 2027-11-29 (ESTIMATED); results not posted in retrieved record.
- Registry NCT01353833: COMPLETED; updated 2012-04-23; enrollment 25 (ACTUAL); primary completion 2011-10 (ACTUAL); results not posted in retrieved record.
- Registry NCT01862120: COMPLETED; updated 2020-11-12; enrollment 24 (ACTUAL); primary completion 2016-07-08 (ACTUAL); results not posted in retrieved record.
- Registry NCT03782636: ACTIVE_NOT_RECRUITING; updated 2025-10-03; enrollment 41 (ACTUAL); primary completion 2023-02-16 (ACTUAL); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: dbi20-0054; s11892-014-0553-6; S2213-8587%2813%2970113-X; journal.pmed.1002139; jci.insight.99306; s00125-020-05200-w; wellcomeopenres.15697.1; jci.insight.147474.